THE HEALTHCARE DECISION COMPANY Trademark

Trademark Overview


On Friday, May 6, 2016, a trademark application was filed for THE HEALTHCARE DECISION COMPANY with the United States Patent and Trademark Office. The USPTO has given the THE HEALTHCARE DECISION COMPANY trademark a serial number of 87028341. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, October 2, 2017. This trademark is owned by Proove Biosciences, Inc.. The THE HEALTHCARE DECISION COMPANY trademark is filed in the Advertising, Business and Retail Services, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Services in the nature of providing business information featuring billing information processing relating to genetic data

Conducting genetic research for scientific research purposes in connection with providing healthcare providers with personalized patient genetic-based medical analysis to enable healthcare provides to prescribe medications to their patients with genetic-based predictions as to how a patient will respond to prescribed medications; Conducting genetic research for scientific research purposes to enable healthcare providers to evaluate how a patient will metabolize medications, to predict a patient's misuse of pain medications, to predict a patient's pain perception or response to opioids, non-opioids, medical detoxification substances, or an epidural with fentanyl, or to protect a patient from NSAID and/or other drug-mediated side effects; Conducting genetic research in connection with providing healthcare providers prescription related guidance; Clinical research services for others, namely, collaborating with physicians, research organizations, patient advocacy groups, charitable organi...

Conducting proprietary genetic testing for medical purposes to enable healthcare providers to provide patients with personalized medical treatment, to improve both the safety and efficacy of a patient's medical treatment, and to reduce costs; Providing genetic testing results and genetic-based medical analysis to healthcare providers to enable healthcare providers for medical purposes to evaluate how a patient will metabolize medications, to predict a patient's misuse of pain medications, to predict a patient's pain perception or response to opioids, non-opioids, medical detoxification substances, or an epidural with fentanyl, or to protect a patient from NSAID and/or other drug-mediated side effects, Providing medical and prescription related guidance to healthcare providers based on the genetic testing results, genetic-based medical analysis, and known drug-drug interactions; Conducting proprietary genetic testing for medical purposes using a simple cheek swab and genomic DNA isolati...
the healthcare decision company

General Information


Serial Number87028341
Word MarkTHE HEALTHCARE DECISION COMPANY
Filing DateFriday, May 6, 2016
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, October 2, 2017
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Disclaimer with Predetermined Text"HEALTHCARE" AND "COMPANY"
Goods and ServicesServices in the nature of providing business information featuring billing information processing relating to genetic data
Goods and ServicesConducting genetic research for scientific research purposes in connection with providing healthcare providers with personalized patient genetic-based medical analysis to enable healthcare provides to prescribe medications to their patients with genetic-based predictions as to how a patient will respond to prescribed medications; Conducting genetic research for scientific research purposes to enable healthcare providers to evaluate how a patient will metabolize medications, to predict a patient's misuse of pain medications, to predict a patient's pain perception or response to opioids, non-opioids, medical detoxification substances, or an epidural with fentanyl, or to protect a patient from NSAID and/or other drug-mediated side effects; Conducting genetic research in connection with providing healthcare providers prescription related guidance; Clinical research services for others, namely, collaborating with physicians, research organizations, patient advocacy groups, charitable organizations, and regulators to address issues related to personalized medicine; Consulting services in the fields of laboratory genetic testing or pharmacogenetics for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Genetic testing for scientific and medical research purposes to medical doctors, genetic scientists and healthcare professionals; Providing information in the field of pharmacogenetics or genetic research resources to medical doctors, genetic scientists and healthcare professionals; Providing genetic testing services for scientific research purposes and information in the field of pharmacogenetics and genetic research for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Research in the field of genetics or pharmacogenetics; Services in the nature of providing genetic testing results for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Providing temporary use of online non-downloadable computer software for controlling or managing patient record information, for the collection, editing, organizing, modifying, transmission, storage or sharing of data and information, and for scientific analysis of genetic sequences or alleles; Providing of genetic-based research information related to personalized medicine to healthcare providers, physicians, research organizations, patient advocacy groups, charitable organizations, and regulators
Goods and ServicesConducting proprietary genetic testing for medical purposes to enable healthcare providers to provide patients with personalized medical treatment, to improve both the safety and efficacy of a patient's medical treatment, and to reduce costs; Providing genetic testing results and genetic-based medical analysis to healthcare providers to enable healthcare providers for medical purposes to evaluate how a patient will metabolize medications, to predict a patient's misuse of pain medications, to predict a patient's pain perception or response to opioids, non-opioids, medical detoxification substances, or an epidural with fentanyl, or to protect a patient from NSAID and/or other drug-mediated side effects, Providing medical and prescription related guidance to healthcare providers based on the genetic testing results, genetic-based medical analysis, and known drug-drug interactions; Conducting proprietary genetic testing for medical purposes using a simple cheek swab and genomic DNA isolation processes; Providing health-related information, consultancy or advisory services for health treatment purposes; Genetic counseling; Genetic tests for health treatment purposes; Providing information, advice or data on genetic testing results for medical purposes; Health treatment services, namely, providing medical prognosis information based on collected and processed genetic data; Medical services in the nature of providing genetic testing and genetic testing results for medical purposes

Classification Information


International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateWednesday, May 11, 2016
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, May 11, 2016
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, May 11, 2016
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMYCROFT BIOANALYTICS, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressSALT LAKE CITY, UT 84111

Party NameProove Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92618

Trademark Events


Event DateEvent Description
Wednesday, October 17, 2018AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Monday, October 2, 2017ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Monday, October 2, 2017ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, March 2, 2017NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, March 2, 2017FINAL REFUSAL E-MAILED
Thursday, March 2, 2017FINAL REFUSAL WRITTEN
Thursday, February 23, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 22, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 22, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 22, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 22, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 22, 2016NON-FINAL ACTION E-MAILED
Monday, August 22, 2016NON-FINAL ACTION WRITTEN
Monday, August 22, 2016ASSIGNED TO EXAMINER
Wednesday, May 11, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, May 10, 2016NEW APPLICATION ENTERED IN TRAM